Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Revenue | $14,523 | $17,399 |
| Operating expenses | ||
| Research and development | 36,553 | 51,597 |
| General and administrative | 7,584 | 13,273 |
| Restructuring and related costs | 42 | 21,043 |
| Total operating expenses | 44,179 | 85,913 |
| Loss from operations | (29,656) | (68,514) |
| Interest income | 1,635 | 3,189 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's G&A?
- Sutro Biopharma (STRO) reported G&A of $7.58M in Q1 2026.
- How has Sutro Biopharma's G&A changed year-over-year?
- Sutro Biopharma's G&A decreased by 42.9% year-over-year, from $13.27M to $7.58M.
- What is the long-term trend for Sutro Biopharma's G&A?
- Over 4 years (2021 to 2025), Sutro Biopharma's G&A has grown at a -7.5% compound annual growth rate (CAGR), from $56M to $41.02M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Sutro Biopharma's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude